SNDX: Syndax Pharmaceuticals, Inc.
Performance
SNDX -36.50%
Watchlist
Select an item
Summary
SNDX at a glance
SNDX returned -36.50% over the past year and -11.48% a year over five years. Its worst drop in that year was -62.74%, smaller than 11% of stocks on Redstone, and its Sharpe ratio of -0.53 beats 11% of stocks on Redstone. It pays no dividends.
Current Drawdown
-62.03%
Rolling Volatility
118.50%
Actions
Metrics
Risk Indicators
Alpha-39.07%
Beta0.81x
Sharpe-0.53
Sortino-0.69
Omega0.91
Calmar-0.58
Martin-1.49
Profile
About SNDX
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab.
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Market cap
- $860M
- Listed
- Mar 2016
- Employees
- 298
- Headquarters
- New York, NY
- Website
- syndax.com
Comparisons